• Login
Forest Laboratories
Divisions and Subsidiaries
  • Forest Pharmaceuticals
  • Forest Laboratories Europe
  • Cerexa, Inc.
  • Forest Laboratories Canada Inc.
  • About Forest
        • Overview
          • Forest identifies, develops, and delivers therapies that make a meaningful difference in people's lives
        • Products
        • Research
        • News
  • Investor Center
        • Overview
          • Forest is building on a strong track record of commercial achievement to deliver important new medicines and strengthen our therapeutic franchises
        • Annual Reports
        • Stock Information
        • Webcasts &
          Presentations
  • Partnerships
        • Overview
          • Forest partners with biotech and pharmaceutical companies to develop and bring promising new medicines to market
        • Capabilities
  • Careers
        • Overview
          • Joining Forest is an opportunity to become part of a forward-thinking community dedicated to helping improve patients' lives through medicine
        • Job Search
  • About Forest
  • Products
  • Research
  • News
    • Media Resources
    • Press Release Archive
    • All Press Releases
    • Business Development News
    • Corporate News
    • Financial News
    • Product News
    • R&D News

Product News

  • 03.30.2005
    Forest Laboratories, Inc. Receives Non-Approvable Letter for Social Anxiety Disorder Indication for Lexapro(R)
  • 03.21.2005
    New COMBUNOX(TM) (Oxycodone HCl and Ibuprofen) Tablets (CII) Now Available for the Short-Term Treatment of Acute, Moderate to Severe Pain
  • 03.01.2005
    Forest Laboratories, Inc. Receives Non-Approvable Letter for Panic Disorder Indication for Lexapro(R)
  • 02.09.2005
    Forest Laboratories Starts Confirmatory Study of Desmoteplase A Novel Investigational Treatment For Acute, Ischemic Stroke
  • 01.11.2005
    First New Treatment for Alcoholism in Ten Years, Now Available Campral(R) (Acamprosate Calcium) Delayed-Release Tablets
  • 11.26.2004
    FDA Approves Combunox(TM) (Oxycodone HCl and Ibuprofen) Tablets (CII) for the Short-Term Treatment Of Acute, Moderate to Severe Pain
  • 09.23.2004
    Glenmark Pharmaceuticals and Forest Laboratories Announce Collaboration Agreement on PDE4 Inhibitor for Asthma and COPD
  • 08.31.2004
    Forest Announces That Neramexane Did Not Demonstrate Statistical Significance in Recently Completed Phase III Trial in Patients with Moderate to Severe Alzheimer's Disease
  • 08.26.2004
    Forest Laboratories Submits Response for Lexapro(R) for Panic Disorder
  • 07.29.2004
    FDA Approves Campral(R) (Acamprosate Calcium) Delayed-Release Tablets for the Treatment of Alcohol Dependence
  • « first
  • ‹ previous
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • next ›
  • last »

ABOUT FOREST

With a unique partnership-focused business model and a strong track record of commercial achievement, Forest has built a pharmaceutical business for today's environment. The Company is fulfilling its objective of making a meaningful difference in patients' lives through an expanded and diversified product portfolio and the most robust pipeline in our history.

CAREERS AT FOREST

Forest employees are driven by a shared passion to help improve patients' lives through medicine. Forest offers a variety of opportunities for experienced professionals, sales professionals, graduate students, and others to build their careers in a collaborative environment. Learn more about joining our team.

 

  • Legal Statement
  • Privacy Policy
  • Contact Us
  • Site Map
© Forest Laboratories, Inc.    085-13000018 6/13